Novatek Pharmaceuticals
Early Stage
Development of immunomodulatory drugs
Overview
Platform
Dealmaker Securities
Start Date
01/04/2023
Close Date
12/14/2023
Min. Goal
$50,000
Max. Goal
$5,000,000
Min. Investment
$500
Security Type
Equity - Common
Series
Series A
Funding Type
RegCF
Price Per Share
$2.00
Pre-Money Valuation
$5,000,000
Location
Pearland, Texas
Industry
Healthcare & Pharmaceuticals
Tech Sector
Biotech
Distribution Model
B2B/B2C
Margin
Medium
Capital Intensity
High
Novatek Pharmaceuticals, with a valuation of $5 million, is raising funds on Dealmaker Securities. It is a pharmaceutical company focused on the development of immunomodulatory drugs related to cancers and infectious diseases. The aim of Novatek Pharmaceuticals’ investigations is to develop drugs to empower naturally-derived immunotherapy and reduce the adverse effects of disease and cytotoxic therapies. Novatek Pharmaceuticals is led by an experienced team and has several products in clinical trials. Mohamed Kaseb founded Novatek Pharmaceuticals in April 2020. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $5 million. The campaign proceeds will be used for marketing, research and development, manufacturing, and general working capital.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$3,446,214 |
$1,148,011 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$16,640 |
$78,288 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$16,640 |
$78,288 |
|
Short-Term Debt |
$2,207,386 |
$1,076,299 |
|
Long-Term Debt |
$2,253,479 |
$0 |
|
Total Liabilities |
$4,460,865 |
$1,076,299 |
Financials as of: 01/04/2023
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Already a member? Log in here.
Ratings 
